Immunotherapy Drugs Market Size by Type, Route of Administration, Indication, Application, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032
Overview
The Immunotherapy Drugs Market size was valued at USD 164.27 Bn in 2024 and the Global Immunotherapy Drugs Market revenue is expected to grow at a CAGR of 10.1% from 2025 to 2032, reaching nearly USD 354.70 Bn by 2032.
Immunotherapy Drugs Market Overview:
The Immunotherapy Drugs Market encompasses treatments designed to enhance or restore the immune system's ability to combat diseases. Immunotherapy leverages various mechanisms, such as checkpoint inhibitors, monoclonal antibodies, CAR-T cell therapy, and vaccines, to target and destroy cancer cells or modulate immune responses. Key applications of immunotherapy Drugs include the treatment of various cancers, including melanoma, lung cancer, and leukaemia, as well as chronic diseases like autoimmune disorders. Market growth is influenced by rising cancer incidence and high investments in research and development. The combination therapies and growth into emerging markets are creating new opportunities for immunotherapy drug adoption.
To know about the Research Methodology :- Request Free Sample Report
In 2024, North America dominated the Immunotherapy Drugs Market due to advanced healthcare infrastructure and high cancer incidence in the region. Companies like DC Therapeutics and Ablynx further increase the market demand through innovation and strong industry presence. Trends like CAR T, ADCs, and mRNA-based therapies is reshaping the immunotherapy market with both strong current value and high future potential. Additionally, the approval of novel therapies and expanding indications for existing treatments contribute to market expansion. Increased awareness and the shift towards precision medicine further fuel demand for immunotherapy drugs, making them a critical area of focus in the evolving landscape of medical treatments.
Immunotherapy Drugs Market Dynamics
Advancements in Personalised Medicine to drive the Immunotherapy Drugs Market Growth
The rising global incidence of cancer is a primary driver for the immunotherapy drugs market. As the number of cancer cases grows due to factors like ageing populations and lifestyle changes, there is a heightened demand for effective treatment options. Immunotherapy offers targeted treatments that can address various cancer types, including those that are resistant to traditional therapies. Progress in personalised medicine, which tailors treatments based on individual genetic and molecular profiles, has significantly impacted the immunotherapy market. Innovations such as personalised cancer vaccines and CAR-T cell therapies demonstrate how tailored approaches can enhance treatment efficacy and minimize side effects. This driver creates a robust market for new and existing immunotherapy drugs, leading to increased research, development, and investment in novel therapies.
Growth of Combination Therapies to create opportunity for the Immunotherapy Drugs Market
Combining immunotherapy with other treatments like chemotherapy, targeted therapies, or radiation offers an opportunity to improve patient outcomes. These combination therapies can enhance efficacy, overcome resistance, and provide a broader range of treatment options. This approach opens new avenues for drug development and market expansion, as it allows companies to offer comprehensive treatment solutions and potentially access new patient demographics. Emerging markets, such as those in Asia-Pacific, Latin America, and the Middle East, are experiencing improvements in healthcare infrastructure and increased healthcare spending. These regions represent opportunities for the introduction and growth of immunotherapy drugs. Expanding into these markets can lead to significant revenue growth and increased market presence, provided companies adapt to local needs and regulatory requirements.
High Treatment Costs and Managing Adverse Effects to create Challenges for the Immunotherapy Drugs Market
Immunotherapy drugs are often expensive due to complex development and manufacturing processes. High costs can restrict access, particularly in lower-income regions or for patients without comprehensive insurance coverage. High costs can limit market penetration and create disparities in treatment access, necessitating strategies to address affordability and improve patient access. Immunotherapy can cause adverse effects, such as immune-related adverse events (irAEs), which may affect various organs and systems. Effective management of these side effects is crucial to ensure patient safety and adherence to treatment.
Immunotherapy Drugs Market Segment Analysis
Based on Type, the Immunotherapy Drugs Market is segmented into Antibody Drugs, Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines and Others. In this Antibody Drugs
dominant market in 2024 and is expected to dominate in the forecasted period due to High clinical efficacy and specificity of monoclonal antibodies (mAbs), including checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 inhibitors and Increasing approvals of biosimilars and next-gen antibodies.
Based on the Route of Administration, the Immunotherapy Drugs Market is segmented into intravenous (IV), oral, intramuscular, subcutaneous, and others. The oral segment dominated the market in 2024 and is expected to hold the market in the forecasted period. Patients generally prefer oral drugs over other forms of administration as they are less invasive and can be self-administered without any medical assistance. This makes the treatment process far more convenient for patients as there is no need for hospital visits or medical supervision every time it is simpler to take pills along with their regular diet rather than regular and painful injections.
Based on the Indication, the Immunotherapy Drugs Market is segmented into Cancer, Autoimmune diseases, Infectious diseases and Others. Cancer dominated the market in 2024 and is expected to dominate in the forecasted period and High prevalence of cancer globally, with increasing incidence driving demand for innovative treatments and widespread adoption of immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines.
Immunotherapy Drugs Market Regional Analysis
The North America region dominated the Immunotherapy Drugs Market in 2024 due to a well-established healthcare system and a high prevalence of cancer
North America accounted for the largest immunotherapy drugs industry share in 2024. The U.S. is a significant contributor to the industry in the region, with a well-established healthcare system and a high prevalence of cancer. The rise in investment in clinical trials and research activities is propelling the immunotherapy drug market dynamics in North America. Regulatory agencies such as the FDA play a crucial role in approving and fast-tracking immunotherapy drugs.
Asia Pacific is the second-largest region in the Immunotherapy Drugs Market
The Asia Pacific region, on the other hand, is witnessing growth and emerging as an important market globally. Rising healthcare expenditure, growing middle-class population, and increasing focus on quality healthcare services are driving the overall oncology market in Asia Pacific, in turn aiding immunotherapy drug adoption. Countries like India, China, Japan, South Korea, and Australia have become key markets within the region.
Immunotherapy Drugs Market Competitive Analysis
Top companies like DC Therapeutics, Ablynx, BeiGene, Hikma Pharmaceuticals and Instituto Butantan hold the largest share in the Immunotherapy Drugs Market, whereas companies like DC Therapeutics and Ablynx standout as DC Therapeutics also called DC3 Therapeutics helps other biotech and pharmaceutical companies with early-stage research for cancer immunotherapy. It offers services like drug screening, biomarker testing, and support for getting FDA approval whereas Ablynx is a creates special small antibodies called Nanobodies to treat autoimmune, inflammatory, and cancer-related diseases. Its main product, caplacizumab, is used for a rare blood clotting disorder (aTTP) also Ablynx has over 45 nanobody drug programs and works with big pharma companies like Merck and Boehringer Ingelheim.
Immunotherapy Drugs Industry Ecosystem
Immunotherapy Drugs Market Key Trends
• Immune Checkpoint Inhibitors & Monoclonal Antibodies-These therapies remain dominant, accounting for 55–77% of market share currently, depending on segment definitions.
• Surging CAR T, ADCs, and Bispecific Antibodies- Cell therapies like CAR T and next-gen biologics (bispecific, trispecific, and ADCs) are among the fastest-growing segments, with CAGRs of 16–18%.
• Personalised Cancer Vaccines & mRNA Therapies- mRNA-based and neoantigen-targeted vaccines (e.g., Autogene cevumeran) are now in late-stage clinical trials, particularly in melanoma and pancreatic cancer
Immunotherapy Drugs Market Key Developments
• May 1, 2023; Acorda Therapeutics (United States)- Entered a long-term global supply agreement with Catalent for manufacturing INBRIJA through 2030; includes capacity expansion and reduced cost of goods starting 2025–2026.
• March 22, 2023; AB Science (France)- Reported a case of complete bone marrow response in an AML patient (MECOM rearranged) treated with AB8939, during Phase I/II trial (AB18001) at low dose, demonstrating potent activity and strong tolerance.
• Sept 11 2023; BeiGene / BeOne Medicines (Beijing, China)- Novartis terminated its licensing deal for PD-1 inhibitor tislelizumab (Tevimbra), returning full rights to BeiGene; around the same time, the European Commission approved tislelizumab in oesophageal cancer.
• June 17, 2024; Hikma Pharmaceuticals (Amman, Jordan)- Acquired Xellia Pharmaceuticals’ U.S. injectable portfolio including eight approved and eleven pipeline products plus manufacturing (Cleveland, Ohio) and R&D center (Zagreb), in a deal worth up to US $185 million; expected to add about US $75 million annual revenue and scale its injectables platform.
• March 4, 2023; Instituto Butantan (São Paulo, Brazil)- Commissioned its new multipurpose vaccine production centre (CPMV) capable of 100 million vaccine doses/year across five platforms.
Immunotherapy Drugs Market Scope:Inquire Before Buying
| Global Immunotherapy Drugs Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2024 | Forecast Period: | 2025-2032 |
| Historical Data: | 2019 to 2024 | Market Size in 2024: | USD 164.27 Bn. |
| Forecast Period 2025 to 2032 CAGR: | 10.1% | Market Size in 2032: | USD 354.70 Bn. |
| Segments Covered: | by Type | Hospital Clinics Public Services Others Antibody Drugs Inhibitor Drugs Interferons and Interleukins Cancer Vaccines Others |
|
| by Route of Administration | Intravenous (IV) Oral Intramuscular Subcutaneous Others |
||
| by Indication | Cancer Autoimmune diseases Infectious diseases Others |
||
| by Application | Cancer Autoimmune and Inflammatory Diseases Hematology Osteology Neurology Others |
||
Immunotherapy Drugs Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Immunotherapy Drugs Market, Key Players:
North America
1. DC Therapeutics – (United States)
2. Acorda Therapeutics – (United States)
3. ELI Lilly and Company – (United States)
4. Bristol-Myers Squibb – (United States)
5. Abbvie – (United States)
6. Amgen Inc – (United States)
7. Johnson & Johnson (Janssen Biotech, Inc.) – (United States)
8. Merck & Co., Inc. – (United States)
9. Viatris Inc. – (United States)
10. Pfizer Inc. – (United States)
11. Vertex Pharmaceuticals Inc. – (United States)
Europe
12. Ablynx – (Belgium)
13. AB Science – (France)
14. AstraZeneca – (United Kingdom/Sweden)
15. GlaxoSmithKline PLC – (United Kingdom)
16. Novartis International AG – (Switzerland)
17. F. Hoffmann-La Roche AG – (Switzerland)
18. Bayer AG – (Germany)
19. Boehringer Ingelheim – (Germany)
20. Immatics Biotechnologies – (Germany)
21. BioNTech SE – (Germany)
Asia Pacific
22. BeiGene (Beijing, China)
23. Innovent Biologics (Suzhou, China)
24. Hengrui Medicine (Lianyungang, China)
25. Junshi Biosciences (Shanghai, China)
Middle East & Africa
26. Hikma Pharmaceuticals (Amman, Jordan)
27. Tabuk Pharmaceuticals (Tabuk, Saudi Arabia)
28. Pharco Pharmaceuticals (Alexandria, Egypt)
South America
29. Instituto Butantan (São Paulo, Brazil)
30. Fiocruz (Bio-Manguinhos/Fiocruz) (Rio de Janeiro, Brazil)
31. Eurofarma (São Paulo, Brazil)
Frequently Asked Questions:
1. Which region has the largest share in the Global Immunotherapy Drugs Market?
Ans: The North America region holds the highest share in 2024.
2. What is the growth rate of the Global Immunotherapy Drugs Market?
Ans: The Global Immunotherapy Drugs Market is growing at a CAGR of 10.1% during the forecasting period 2025-2032.
3. What is the scope of the Global Immunotherapy Drugs market report?
Ans: The Global Immunotherapy Drugs Market report helps with the PESTEL, Porter's, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in the Global Immunotherapy Drugs market?
Ans: The important key players in the Global Immunotherapy Drugs Market are – DC Therapeutics, Acorda Therapeutics, Ablynx and AB Scienc.
5. What is the study period of this market?
Ans: The Global Immunotherapy Drugs Market is studied from 2019 to 2024.